S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

StageZero Life Sciences Stock Forecast, Price & News

+0.01 (+18.71%)
(As of 06/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1,000 shs
Average Volume
2,871 shs
Market Capitalization
$6.39 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive SZLSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for StageZero Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

SZLSF Stock Forecast (MarketRank)

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
StageZero Life Sciences logo

About StageZero Life Sciences (OTCMKTS:SZLSF)

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.

SZLSF Stock News Headlines

StageZero Life Sciences CFO resigns
StageZero Life Sciences Launches AVRT(TM) in the UK
See More Headlines

Industry, Sector and Symbol

Diagnostic substances
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Net Income
$-7.48 million
Pretax Margin


Sales & Book Value

Annual Sales
$5.07 million
Book Value
$0.03 per share


Free Float
Market Cap
$6.39 million
Not Optionable

StageZero Life Sciences Frequently Asked Questions

How has StageZero Life Sciences' stock price performed in 2022?

StageZero Life Sciences' stock was trading at $0.2303 at the beginning of the year. Since then, SZLSF stock has decreased by 72.4% and is now trading at $0.063450.
View the best growth stocks for 2022 here

When is StageZero Life Sciences' next earnings date?

StageZero Life Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for StageZero Life Sciences

How were StageZero Life Sciences' earnings last quarter?

StageZero Life Sciences Ltd. (OTCMKTS:SZLSF) issued its earnings results on Thursday, March, 31st. The company reported ($0.05) earnings per share (EPS) for the quarter. The business had revenue of $1.50 million for the quarter. StageZero Life Sciences had a negative net margin of 20.01% and a negative trailing twelve-month return on equity of 305.71%.
View StageZero Life Sciences' earnings history

Who are StageZero Life Sciences' key executives?

StageZero Life Sciences' management team includes the following people:
  • Mr. James R. Howard-Tripp, Exec. Chairman & CEO
  • Prof. Choong-Chin Liew, Co-Founder
  • Mr. Warren Whitehead C.M.A., CPA, Chief Accountant (Age 70)
  • Mr. David Suria, Sr. Scientist

What is StageZero Life Sciences' stock symbol?

StageZero Life Sciences trades on the OTCMKTS under the ticker symbol "SZLSF."

How do I buy shares of StageZero Life Sciences?

Shares of SZLSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is StageZero Life Sciences' stock price today?

One share of SZLSF stock can currently be purchased for approximately $0.06.

How much money does StageZero Life Sciences make?

StageZero Life Sciences (OTCMKTS:SZLSF) has a market capitalization of $6.39 million and generates $5.07 million in revenue each year. The company earns $-7.48 million in net income (profit) each year or ($0.03) on an earnings per share basis.

How many employees does StageZero Life Sciences have?

StageZero Life Sciences employs 51 workers across the globe.

How can I contact StageZero Life Sciences?

StageZero Life Sciences' mailing address is 70 East Beaver Creek Road Unit 30, Richmond Hill A6, L4B 3B2. The official website for StageZero Life Sciences is www.stagezerolifesciences.com. The company can be reached via phone at (855) 420-7140, via email at [email protected], or via fax at 905-209-2031.

This page (OTCMKTS:SZLSF) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.